Literature DB >> 4171301

Metabolism of gamma globulin fragments in normal and agammaglobulinemic persons.

C A Janeway, E Merler, F S Rosen, S Salmon, J D Crain.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1968        PMID： 4171301     DOI： 10.1056/NEJM196804252781701

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  11 in total

Review 1.  Criteria for the appropriate drug utilisation of immunoglobulin.

Authors:  P Thürmann; S Harder
Journal:  Pharmacoeconomics       Date:  1996-05       Impact factor: 4.981

2.  Clinical trials of sulfonated immunoglobulin preparation for intravenous administration. II. Adverse reactions.

Authors:  S Matsumoto; N Kobayashi; N Gohya
Journal:  Eur J Pediatr       Date:  1981-05       Impact factor: 3.183

3.  Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments.

Authors:  H R Ochs; T W Smith
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

4.  Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon.

Authors:  T W Smith; B L Lloyd; N Spicer; E Haber
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

5.  [Problems of intravenous gammaglobulin therapy (author's transl)].

Authors:  J Ring; K H Duswald
Journal:  Klin Wochenschr       Date:  1980-08-15

Review 6.  [Therapeutic use of immunoglobulins in children (author's transl)].

Authors:  W H Hitzig
Journal:  Blut       Date:  1980-03

7.  Granulocytic function after administration of pepsin treated human gammaglobulin.

Authors:  L Lindquist; C Jarstrand; P Lundbergh
Journal:  Infection       Date:  1978       Impact factor: 3.553

8.  The isolation of digoxin-specific antibody and its use in reversing the effects of digoxin.

Authors:  J Curd; T W Smith; J C Jaton; E Haber
Journal:  Proc Natl Acad Sci U S A       Date:  1971-10       Impact factor: 11.205

9.  Intravenous immunoglobulin therapy for antibody deficiency.

Authors:  M T Nolte; B Pirofsky; G A Gerritz; B Golding
Journal:  Clin Exp Immunol       Date:  1979-05       Impact factor: 4.330

Review 10.  Review of intravenous immunoglobulin replacement therapy trials for primary humoral immunodeficiency patients.

Authors:  H W Schroeder; C J Dougherty
Journal:  Infection       Date:  2012-09-12       Impact factor: 3.553
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.